Nanotechnology Now - Press Release: "New Nano Vaccine Fights Leishmaniasis"

Home > Press > New Nano Vaccine Fights Leishmaniasis

Abstract:
Iranian researchers at the Pharmaceutical School of Tabriz University of Medical Sciences, in cooperation with their colleagues from Shiraz University of Medical Sciences and Exir Pharmaceutical Company, succeeded in designing a nano vaccine in order to prevent leishmaniasis disease.

New Nano Vaccine Fights Leishmaniasis

Tehran, Iran | Posted on August 23rd, 2011

"The purpose of the present study was to design a nano vaccine against leishmaniasis diseases that exists in three forms of dermal, mucous, and visceral," Dr. Mohammad Ali Danesh, one of the researchers of the project, said.

"Leishmaniasis is a long-term therapy parasitic disease. According to WHO prediction, approximately 12 million people all over the world suffer from leishmaniasis of which 60 thousand die every year," he continued.

Elaborating on the results of the study, the researcher said, "Results indicate that chitosan is able to increase the immunogenicity of superoxide dismutase B1 (SODB1). This is done via increasing the size of the antigen for the better stimulation of the immune system and also via the role of the adjuvant (chitosan). The single and triple dose injections of nanoparticles containing SODB1 show a similar result in the cellular immunological stimulation, which is higher than other groups."

The results make possible the production of a single-dose nano vaccine for Leishmaniasis and the similar protozoal infections due to the similarity of SODB1 in protozoan parasites.

According to Dr. Danesh, no effective vaccine has so far been confirmed against Leishmaniasis, and the present research creates new hopes in this regard.

He said that the next step in their research would be the continuation of studies on animals and the use of other adjuvant in addition to chitosan and measuring the other cellular immunological indices.

"It takes any new vaccine at least 12 years to come to the market, and it must undergo various tests on animals and humans at different stages, and it must be approved by one of the international organizations," Dr. Danesh explained.

####

For more information, please click here

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: